Literature DB >> 10076716

International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury.

M A Shipp1, M D Abeloff, K H Antman, G Carroll, A Hagenbeek, M Loeffler, E Montserrat, J A Radford, G Salles, N Schmitz, M Symann, J O Armitage, B Coiffier, T Philip.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10076716     DOI： 10.1023/a:1008397220178

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy.

Authors:  Stephen M Beard; Lucy Wall; Louise Gaffney; Fiona Sampson
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  SEOM clinical guidelines for the treatment of diffuse large B-cell lymphoma.

Authors:  José Gómez Codina; Pilar Sabín Domínguez; Mariano Provencio Pulla; Antonio Rueda Domínguez; Dolores Isla Casado
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

3.  The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Authors:  Iordanis Gravanis; Kyriaki Tzogani; Paula van Hennik; Pieter de Graeff; Petra Schmitt; Jan Mueller-Berghaus; Tomas Salmonson; Christian Gisselbrecht; Edward Laane; Lothar Bergmann; Francesco Pignatti
Journal:  Oncologist       Date:  2015-11-30

4.  A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma.

Authors:  Zizheng Wu; Qingpei Guan; Xue Han; Xianming Liu; Lanfang Li; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Xianhuo Wang; Huilai Zhang
Journal:  Aging (Albany NY)       Date:  2021-10-05       Impact factor: 5.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.